Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Aug 21;39(32):2997-2999.
doi: 10.1093/eurheartj/ehy018.

The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy

Davor Pavlovic  1 , Paulus Kirchhof  1   2   3 , Larissa Fabritz  1   3
Affiliations
Comment

The RACE-3 is on: double-locking sinus rhythm by upstream and downstream therapy

Davor Pavlovic et al. Eur Heart J. .
No abstract available

PubMed Disclaimer

Figures

Take home figure
Take home figure
Illustration of major upstream and downstream drivers of atrial fibrillation (AF) and direct and indirect links to cardiovascular outcomes. Upstream therapy targets major indirect drivers of AF, including high blood pressure, renin-angiotensin-aldosterone-system (RAAS) activation, reactive oxygen species (ROS), increased sodium load, dyslipoproteinaemia and epicardial fat. Upstream therapy thus also reduces atrial load and strain, fibrosis and fat infiltration in the atria. Rhythm control therapy directly targets triggered activity, action potential duration (APD) shortening and slowed conduction across the atria. Inset; atrial electrical function can be altered by fatty deposition (shown in yellow) and interstitial fibrosis (shown in red). Dashed lines indicate less established links, solid lines established links to a delta of cardiovascular complications. ICV, inferior caval vein; LA, left atrium; LPV, left pulmonary vein; RA, right atrium; SAN, sinoatrial node.
None
See this image and copyright information in PMC

Comment on

References

    1. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K.. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–2962. - PubMed
    1. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AG, XANTUS Investigators. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J 2016;37:1145–1153. - PMC - PubMed
    1. Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, Schilling RJ, Schmitt J, Zamorano JL.. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events–European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014;16:6–14. - PMC - PubMed
    1. Lip GY, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L, Darabantiu D, Crijns HJ, Kirchhof P, Vardas P, Tavazzi L, Maggioni AP, Boriani G.. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J 2014;35:3365–3376. - PubMed
    1. Kirchhof P. The future of atrial fibrillation management: integrated care and stratified therapy. Lancet 2017;390:1873–1887. - PubMed

Publication types